FDA Criticizes Novo Nordisk's Wegovy Ad for Misleading Claims

The U.S. Food and Drug Administration (FDA) has raised concerns over a television advertisement by Novo Nordisk for its new weight-loss drug, Wegovy. According to Jin10, the FDA stated that the ad contains 'false or misleading' claims about the drug's weight-loss effects, exacerbating the pharmaceutical company's recent challenges. The FDA noted that the advertisement misleadingly suggests that the oral form of Wegovy has advantages over other weight-loss medications. In a letter to Novo Nordisk dated February 5, the agency specifically questioned promotional phrases such as 'live lightly' and 'the future is promising.' Furthermore, the FDA highlighted that these phrases misleadingly imply benefits beyond actual weight loss, such as emotional relief, reduced psychological burden, and providing hope or direction in patients' lives, positioning the drug as a solution for broader life challenges rather than a treatment for a specific condition.